Jason Drew Smith, the General Counsel of $URGN, sold 1,608 shares of the company on 02-03-2026 for an estimated $31,661. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.0% of their shares of this class of stock. Following this trade, they now own 51,326 shares of this class of $URGN stock.
$URGN Insider Trading Activity
$URGN insiders have traded $URGN stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $URGN stock by insiders over the last 6 months:
- MARK SCHOENBERG (Chief Medical Officer) has made 0 purchases and 5 sales selling 18,244 shares for an estimated $411,819.
- JASON DREW SMITH (General Counsel) has made 0 purchases and 4 sales selling 8,999 shares for an estimated $176,308.
- CHRIS DEGNAN (Chief Financial Officer) sold 2,203 shares for an estimated $37,120
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$URGN Hedge Fund Activity
We have seen 82 institutional investors add shares of $URGN stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 4,216,084 shares (+inf%) to their portfolio in Q3 2025, for an estimated $84,110,875
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,506,000 shares (-68.9%) from their portfolio in Q3 2025, for an estimated $30,044,700
- MILLENNIUM MANAGEMENT LLC added 874,706 shares (+147.2%) to their portfolio in Q3 2025, for an estimated $17,450,384
- D. E. SHAW & CO., INC. added 861,501 shares (+3140.5%) to their portfolio in Q3 2025, for an estimated $17,186,944
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 830,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $16,558,500
- TCG CROSSOVER MANAGEMENT, LLC added 717,347 shares (+inf%) to their portfolio in Q3 2025, for an estimated $14,311,072
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 687,475 shares (+inf%) to their portfolio in Q3 2025, for an estimated $13,715,126
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$URGN Analyst Ratings
Wall Street analysts have issued reports on $URGN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 10/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/27/2025
- Piper Sandler issued a "Overweight" rating on 08/19/2025
To track analyst ratings and price targets for $URGN, check out Quiver Quantitative's $URGN forecast page.
$URGN Price Targets
Multiple analysts have issued price targets for $URGN recently. We have seen 3 analysts offer price targets for $URGN in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $33.0 on 01/23/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $40.0 on 10/27/2025
- Kelsey Goodwin from Piper Sandler set a target price of $36.0 on 08/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
